<DOC>
	<DOCNO>NCT01159054</DOCNO>
	<brief_summary>Patients kidney failure hemodialysis extremely high rate cardiovascular disease include atherosclerotic cardiovascular disease . This , least part , due chronic inflammatory status usually see patient . Here try see treatment extended release nicotinic acid ( Niaspan ) reduce overall inflammatory burden ( general ) atherosclerotic plaque inflammation ( particular ) .</brief_summary>
	<brief_title>Novel Pathways Manage Inflammation Atherosclerosis Dialysis Patients : Role Nicotinic Acid</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>A signed consent form ; Male Female , 18 year old ; Diagnosed ESRD , maintenance hemodialysis least six ( 6 ) month ; Subject must able understand provide informed consent ; No known contraindication therapy nicotinic acid ; Female subject childbearing potential must willing acceptable form birth control duration study two month stop take study drug . Any patient medical condition take medication would contraindicate use extend release niacin , active peptic ulcer disease ; History severe allergic reaction study medication ; History active infection acute gouty attack within 2 week prior enrollment ; Known serological positivity HIV , HBsAg , HCV Ab ; HbA1C &gt; 9 ; Total CK three time upper limit normal ; Elevation liver function test time entry ( AST and/or ALT &gt; 2 time upper limit normal ) ; History drug , alcohol , chemical abuse within 6 month prior enrollment ; History malignancy except adequately treat insitu cervical carcinoma , adequately treat basal squamous cell carcinoma skin ; History inflammatory disease SLE , rheumatoid arthritis ulcerative colitis ; Patients currently pharmacological dos nicotinic acid ; Patients receive chronic antiinflammatory therapy ; Patients average baseline hsCRP level &gt; 20 mg/L &lt; 1 mg/L ; Patients FDGPET/CT dual scan contraindicate ( e.g. , pregnant patient severe allergy IV contrast ; pregnancy test perform female subject 18 45 year age prior scan )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>